Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Digestive System Neoplasms Clinical Trials

A listing of Digestive System Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (63) clinical trials

Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies

Arm A: Study Drug Administration: You will receive utomilumab by vein over 60 minutes on Day 1 of each 28-day study cycle. Starting on Day 1 of Cycle 3, you will receive avelumab by vein over 60 minutes on Days 1 and 15 of each cycle after that. You will ...

Phase

Oncogeriatric Intervention and Follow-up at Home

Cancer of the head and neck (HNC), lung (LC), upper gastrointestinal channel (CUGI) and colo-rectal cancer (CRC) accounts for approximately 40% of cancer incidence in elderly people (defined as 70 years) in Denmark (DK). The four cancers account for more than 50% of the annual cancer-related deaths in DK. Incidence ...

Phase N/A

Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors

The purpose of the Dose Escalation Phase is to examine the safety and determine the maximum tolerated dose of CGX1321 when administered to subjects with advanced GI tumors that have relapsed or are refractory to or not considered medically suitable to receive standard of care treatment. Once the dose is ...

Phase

Educational Intervention to Increase the Emotional Competence of Patients With Oesogastric and Bronchopulmonary Cancers

After the end of treatments, cancer patients face a difficult time because it is expected that they return to normal, but at the same time they still have to struggle with the aftermath of cancer and fear of recurrence. This is why there is room in this period for an ...

Phase N/A

A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers

This is a phase 2 clinical trial of nivolumab combined with ipilimumab in subjects with rare cancers. This study will allow an evaluation of the clinical benefit, as measured by progression free survival (PFS) and overall survival (OS), provided by nivolumab combined with ipilimumab. If the safety profile is acceptable ...

Phase

Skeletal Muscle Energy Metabolism in Undernourished Patients With Gastrointestinal Cancer

Undernutrition associated with cancer, or cancer cachexia results from a deterioration of the energy balance that leads to a gradual mobilization of energy reserves in the body and to increasing deterioration of the nutritional status of patients. This will thus significantly reduce quality of life and survival of patients with ...

Phase N/A

TAK228 With Carbo and Taxol in Advanced Malignancies

Study Groups: If participant is found to be eligible to take part in this study, participant will be assigned to a dose level of TAK-228, carboplatin, and paclitaxel based on when participant joins this study. Up to 6 dose levels of TAK-228, carboplatin, and paclitaxel will be tested. Up to ...

Phase

A Study of FPA144 Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer

Phase 1 is an open-label dose-escalation of FPA144 in combination with mFOLFOX6. Eligible patients will have unresectable locally advanced or metastatic GI cancer of any type and be candidates to receive at least 2 doses of mFOLFOX6 chemotherapy. FGFR2 status is not a requirement for enrollment. FGFR2 status will be ...

Phase

Development of Clinical and Biological Database

Implementation of a translational research project is part of the Cancer Plan 2014-2019 and its axis 5 "Advancing clinical and translational research in oncology", and more precisely Action 5.1. The national health strategy launched by the Minister of Health and the Minister of Research will allow a better integration between ...

Phase N/A

Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1

This Phase I dose escalation study will evaluate Procaspase Activating Compound-1 (PAC-1), a small molecule that activates procaspase -3 to caspase-3, resulting in apoptosis of cancer cells, in patients with advanced malignancies. PAC-1 is taken orally on days 1-21 of a 28-day cycle. The maximum tolerated dose (MTD) of PAC-1 ...

Phase